The Latest Breaking News from Merck

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts.

Merck & Co. is projected to report its third-quarter earnings result at the end of this month, and analysts expect a double-digit profit dip.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Indexes were mixed early Wednesday. Nvidia added gains after clearing a trendline entry on Tuesday. Trump Media & Technology soared.

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.